Oric Pharmaceuticals (ORIC) Competitors $10.56 -0.44 (-4.00%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$10.54 -0.02 (-0.14%) As of 09/19/2025 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. PCVX, KRYS, ARWR, ACAD, ADMA, AAPG, MTSR, MIRM, ZLAB, and PTGXShould you be buying Oric Pharmaceuticals stock or one of its competitors? The main competitors of Oric Pharmaceuticals include Vaxcyte (PCVX), Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Ascentage Pharma Group International (AAPG), Metsera (MTSR), Mirum Pharmaceuticals (MIRM), Zai Lab (ZLAB), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Oric Pharmaceuticals vs. Its Competitors Vaxcyte Krystal Biotech Arrowhead Pharmaceuticals ACADIA Pharmaceuticals ADMA Biologics Ascentage Pharma Group International Metsera Mirum Pharmaceuticals Zai Lab Protagonist Therapeutics Vaxcyte (NASDAQ:PCVX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership. Which has more risk and volatility, PCVX or ORIC? Vaxcyte has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Do analysts prefer PCVX or ORIC? Vaxcyte presently has a consensus price target of $106.25, indicating a potential upside of 234.65%. Oric Pharmaceuticals has a consensus price target of $17.29, indicating a potential upside of 63.69%. Given Vaxcyte's stronger consensus rating and higher probable upside, equities research analysts plainly believe Vaxcyte is more favorable than Oric Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Oric Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Does the media favor PCVX or ORIC? In the previous week, Vaxcyte had 5 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 7 mentions for Vaxcyte and 2 mentions for Oric Pharmaceuticals. Vaxcyte's average media sentiment score of 1.12 beat Oric Pharmaceuticals' score of 0.93 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, PCVX or ORIC? Vaxcyte is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$463.93M-$4.11-7.73Oric PharmaceuticalsN/AN/A-$127.85M-$1.89-5.59 Do institutionals and insiders have more ownership in PCVX or ORIC? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 6.8% of Oric Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is PCVX or ORIC more profitable? Vaxcyte's return on equity of -16.85% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -16.85% -15.92% Oric Pharmaceuticals N/A -51.75%-47.09% SummaryVaxcyte beats Oric Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricOric PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.07B$3.16B$5.79B$10.40BDividend YieldN/A2.37%5.63%4.60%P/E Ratio-5.5920.5276.4826.75Price / SalesN/A446.54531.72124.23Price / CashN/A46.0037.9261.55Price / Book3.069.6613.726.40Net Income-$127.85M-$53.02M$3.29B$271.62M7 Day Performance-2.04%3.12%2.65%3.46%1 Month Performance11.04%7.57%6.01%9.87%1 Year Performance-6.13%11.17%80.02%28.45% Oric Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICOric Pharmaceuticals4.5055 of 5 stars$10.56-4.0%$17.29+63.7%-5.4%$1.07BN/A-5.5980Positive NewsHigh Trading VolumePCVXVaxcyte2.014 of 5 stars$31.00-3.6%$106.25+242.7%-72.9%$4.18BN/A-7.54160Positive NewsKRYSKrystal Biotech4.9548 of 5 stars$155.71+8.4%$209.00+34.2%-11.3%$4.16B$359.21M31.65210High Trading VolumeARWRArrowhead Pharmaceuticals4.2169 of 5 stars$28.67-3.5%$43.14+50.5%+45.2%$4.11B$3.55M-22.40400Insider TradeAnalyst RevisionACADACADIA Pharmaceuticals4.1471 of 5 stars$24.67+4.5%$29.65+20.2%+48.7%$3.98B$957.80M18.55510ADMAADMA Biologics3.5058 of 5 stars$15.30-5.0%$27.67+80.8%-19.4%$3.84B$426.45M17.79530Positive NewsAAPGAscentage Pharma Group InternationalN/A$38.63-4.5%N/AN/A$3.77B$134.35M0.00600Gap DownMTSRMetseraN/A$34.21-4.1%$63.50+85.6%N/A$3.75BN/A0.0081MIRMMirum Pharmaceuticals2.9878 of 5 stars$74.19-0.2%$74.44+0.3%+89.0%$3.73B$336.89M-61.31140ZLABZai Lab3.1373 of 5 stars$31.92-2.7%$56.35+76.5%+54.8%$3.67B$398.99M-15.651,869Gap UpPTGXProtagonist Therapeutics1.8648 of 5 stars$58.38-0.8%$67.73+16.0%+35.5%$3.66B$209.18M83.40120Analyst Forecast Related Companies and Tools Related Companies Vaxcyte Competitors Krystal Biotech Competitors Arrowhead Pharmaceuticals Competitors ACADIA Pharmaceuticals Competitors ADMA Biologics Competitors Ascentage Pharma Group International Competitors Metsera Competitors Mirum Pharmaceuticals Competitors Zai Lab Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORIC Stock Alerts